Stocktoria
Serina Therapeutics, Inc. SER
Serina Therapeutics, Inc. (SER) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $130,000 at a -14755.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SER | Serina Therapeutics, Inc. | 2/9 | — | — | — |
| BFRG | BullFrog AI Holdings, Inc. | 1/9 | — | — | — |
| LSTA | LISATA THERAPEUTICS, INC. | 1/9 | — | — | — |
| ATNM | Actinium Pharmaceuticals, Inc. | 2/9 | — | — | — |
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
| INO | INOVIO PHARMACEUTICALS, INC. | — | — | — | — |
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
FAQ
Is SER financially healthy?
Serina Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does SER pay a dividend?
No, Serina Therapeutics, Inc. does not currently pay a dividend.
How profitable is SER?
In FY2025, Serina Therapeutics, Inc. had a net margin of -14755.4%.
What is the analyst price target for SER?
The average Wall-Street price target for Serina Therapeutics, Inc. is $11.00, about 290.1% above the recent price, from 1 analysts.
Is SER a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Serina Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.